Erythropoietin Stimulating Agent Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Erythropoietin Stimulating Agent Market
Erythropoietin Stimulating Agent Market: By Type (Epoetin-alfa, Epoetin-beta, Epoetin-omega, Epoetin-delta, Darbepoetin-alfa); By Disease Cured (Oncology diseases, Kidney Disorders, Others) & By Geography (North America, Europe, Others) -Forecast (2016-2021)
Report Code : HCR 0205
Updated Date: 10 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Erythropoietin is a hormone released by the human renal system (kidney) which increases the rate of production of red blood cells in response to falling levels of oxygen in the tissues and helps in the process of erythropoiesis (production of red blood cells). Erythropoietin stimulating agents (EPO) are used to treat people undergoing chemotherapy or treatments related to HIV. Globally, demand for Erythropoietin drugs (EPO) is driven by an increasing population with HIV, Cancer and Renal diseases.

This report identifies the erythropoietin stimulating agents market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to erythropoietin stimulating agents market.
 
Erythropoietin Stimulating Agent Market

Globally, North America dominated the market for erythropoietin stimulating agents in 2015 with higher awareness about erythropoietin drugs and higher cases of the renal, oncological and anaemic diseases. However by 2021, Europe, which closely followed North America as second largest regional market for erythropoietin stimulating agents is expected to overcome North America to dominate the global market. However, the Asia-Pacific market for erythropoietin stimulating agents is expected to post strong growth during the period of study due to increasing purchasing power, rapid development in infrastructure, growing medical tourism, and expansion in available treatments.

This report on erythropoietin stimulating agents also covers different type erythropoietin stimulating agents, diseases cured and market size in various geographical regions.
  • The report covers major type of erythropoietin stimulating agents, some of the major types available are as follows: Epoetin-alfa, Epoetin-beta, Epoetin-omega,Epoetin-delta and Darbepoetin-alfa
  • On the basis of disease cured with the help of erythropoietin drugs, this report on erythropoietin stimulating agents market is segmented as below covering all major disease cured: Oncology diseases, Kidney Disorders (End stage renal disease (ESRD) and Dialysis), Anemia, Neural Disease and Wound healing
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for erythropoietin stimulating agents in each of the region.

This report identifies all the major companies operating in the erythropoietin stimulating agents market. Some of the major companies’ profiles in detail are as follows:
  • Teva Pharmaceutical Industries Ltd.
  • Ranbaxy Laboratories Ltd.
  • Intas Pharmaceuticals      
  • Biocon Limited     
  • LG Life Sciences Ltd.
1. Erythropoietin Stimulating Agent – Market Overview
2. Executive Summary
3. 
Erythropoietin Stimulating Agent Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Erythropoietin Stimulating Agent – Market Forces
   4.1. Drivers
      4.1.1. Globally increasing cases of HIV, Cancer and Renal diseases
   4.2. Restraints
      4.2.1. Higher cost and duration of EPO therapeutics
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Erythropoietin Stimulating Agent Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Erythropoietin Stimulating Agent Market, By Product Type
   6.1. Epoetin-alfa
   6.2. Epoetin-beta
   6.3. Epoetin-omega
   6.4. Epoetin-delta
   6.5. Darbepoetin-alfa
7. Erythropoietin Stimulating Agent Market, By Disease Cured
   7.1. Oncology diseases
   7.2. Kidney Disorders
      7.2.1. End stage renal disease (ESRD)
      7.2.2. Dialysis
   7.3. Anemia
   7.4. Neural Disease
   7.5. Wound healing
8. Erythropoietin Stimulating Agent Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Erythropoietin Stimulating Agent – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles
   10.1. Teva Pharmaceutical Industries Ltd.
      10.1.1. Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Ranbaxy Laboratories Ltd.
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Intas Pharmaceuticals      
      10.3.1. Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. Biocon Limited     
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. LG Life Sciences Ltd.  
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Hospira Inc.   
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Roche Diagnostics   
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Johnson & Johnson      
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. Amgen Inc.
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. Celltrion, Inc      
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll